Your browser doesn't support javascript.
loading
Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer.
Perets, R; Bar, J; Rasco, D W; Ahn, M-J; Yoh, K; Kim, D-W; Nagrial, A; Satouchi, M; Lee, D H; Spigel, D R; Kotasek, D; Gutierrez, M; Niu, J; Siddiqi, S; Li, X; Cyrus, J; Chackerian, A; Chain, A; Altura, R A; Cho, B C.
Afiliação
  • Perets R; Department of Oncology, Rambam Medical Center, Technion-Israel Institute of Technology, Haifa, Israel.
  • Bar J; Cancer Center, Chaim Sheba Medical Center at Tel HaShomer, Ramat Gan, and Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Rasco DW; Phase I, START, San Antonio, USA.
  • Ahn MJ; Department of Medicine, Samsung Medical Center, Sungkyunkwan University of Medicine, Seoul, South Korea.
  • Yoh K; Department of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Kim DW; Department of Hemato Oncology, Medical Oncology Center, and Personalized Cancer Medicine Center, Seoul National University Hospital, Seoul, South Korea.
  • Nagrial A; Department of Cancer and Hematology, Blacktown Hospital and University of Sydney, Sydney, Australia.
  • Satouchi M; Department of Thoracic Oncology, Hyogo Cancer Center, Akashi, Japan.
  • Lee DH; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
  • Spigel DR; Department of Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, USA.
  • Kotasek D; Department of Medical Oncology, Adelaide Cancer Centre and University of Adelaide, Kurralta Park, Australia.
  • Gutierrez M; Department of Hematology, Hematology Oncology, and Medical Oncology, Hackensack University Medical Center, Hackensack, USA.
  • Niu J; Department of Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, USA.
  • Siddiqi S; MRL, Merck & Co., Inc., Kenilworth, NJ, Kenilworth, USA.
  • Li X; MRL, Merck & Co., Inc., Kenilworth, NJ, Kenilworth, USA.
  • Cyrus J; MRL, Merck & Co., Inc., Kenilworth, NJ, Kenilworth, USA.
  • Chackerian A; Department of Discovery Oncology, Merck & Co., Inc., Kenilworth, USA.
  • Chain A; MRL, Merck & Co., Inc., Kenilworth, NJ, Kenilworth, USA.
  • Altura RA; MRL, Merck & Co., Inc., Kenilworth, NJ, Kenilworth, USA.
  • Cho BC; Division of Medical Oncology, Yonsei Cancer Center, Seoul, South Korea. Electronic address: CBC1971@yuhs.ac.
Ann Oncol ; 32(3): 395-403, 2021 03.
Article em En | MEDLINE | ID: mdl-33276076
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Pulmonar de Células não Pequenas / Neoplasias Pulmonares Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article